Tafluprost Patent Expiration

Tafluprost is used for reducing elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. It was first introduced by Thea Pharma Inc in its drug Zioptan on Feb 10, 2012. 4 different companies have introduced drugs containing Tafluprost.


Tafluprost Patents

Given below is the list of patents protecting Tafluprost, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zioptan US10864159 Method and composition for treating ocular hypertension and glaucoma May 28, 2029 Thea Pharma
Zioptan US9999593 Method and composition for treating ocular hypertension and glaucoma May 28, 2029 Thea Pharma
Zioptan US5886035 Difluoroprostaglandin derivatives and their use Dec 18, 2017

(Expired)

Thea Pharma



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tafluprost's patents.

Given below is the list recent legal activities going on the following patents of Tafluprost.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 29 May, 2024 US10864159
Payment of Maintenance Fee, 4th Year, Large Entity 01 Dec, 2021 US9999593
Patent Issue Date Used in PTA Calculation 15 Dec, 2020 US10864159
Recordation of Patent Grant Mailed 15 Dec, 2020 US10864159
Email Notification 25 Nov, 2020 US10864159
Issue Notification Mailed 24 Nov, 2020 US10864159
Application Is Considered Ready for Issue 12 Nov, 2020 US10864159
Dispatch to FDC 12 Nov, 2020 US10864159
Issue Fee Payment Received 11 Nov, 2020 US10864159
Issue Fee Payment Verified 11 Nov, 2020 US10864159


Tafluprost's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Tafluprost Generic API Manufacturers

Several generic applications have been filed for Tafluprost. The first generic version for Tafluprost was by Micro Labs Ltd and was approved on Aug 19, 2019. And the latest generic version is by Ingenus Pharmaceuticals Llc and was approved on Apr 5, 2024.

Given below is the list of companies who have filed for Tafluprost generic, along with the locations of their manufacturing plants worldwide.


1. INGENUS PHARMS LLC

Ingenus Pharmaceuticals Llc has filed for 1 generic for Tafluprost. Given below are the details of the strengths of this generic introduced by Ingenus Pharms Llc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.0015%

solution/drops Discontinued OPHTHALMIC N/A Apr 5, 2024





2. MICRO LABS

Micro Labs Ltd has filed for 1 generic for Tafluprost. Given below are the details of the strengths of this generic introduced by Micro Labs.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.0015%

solution/drops Prescription OPHTHALMIC AT Aug 19, 2019


Manufacturing Plant Locations
New

Micro Labs's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Micro Labs as present at those locations.

Country City Firm Name
India
Bangalore Micro Labs Limited
Bengaluru Micro Labs Limited, Central Analytical Laboratory
Bengaluru Micro Labs Limited
Verna Micro Labs Limited





3. SANDOZ

Sandoz Inc has filed for 1 generic for Tafluprost. Given below are the details of the strengths of this generic introduced by Sandoz.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.0015%

solution/drops Prescription OPHTHALMIC AT Jan 28, 2022


Manufacturing Plant Locations
New

Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.

Country City Firm Name
Austria
Kundl Sandoz GmbH
Langkampfen Sandoz GmbH
United States
East Hanover Sandoz Incorporated
Princeton Sandoz Inc
Spain
Palafolls Sandoz Industrial Products, S.A.
Les Franqueses Del Valles Sandoz Industrial Products S.A.
India
Navi Mumbai Sandoz Private Limited